AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Implementation of Machine Learning and Hemodynamic Profiles Based Clinical Decision Support Systems for Personalized Guideline Accordant Antihypertensive Regimens in Primary Care: a Pragmatic Cluster Randomized Controlled Trial

RecruitingNAAges 35 Years - 79 YearsAllChina National Center for Cardiovascular Diseases
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This trial is a prospective, multicenter, single-blind, three-arm parallel-group, cluster randomized controlled trial assessing the effectiveness and safety of two types of CDSS in primary care settings in China. Primary care sites are randomized to one of the intervention arms or the control arm (1:1:1 ratio) using computer-generated random numbers stratified by region and administrative categories of the primary healthcare institutions (including community health centers, community health stations, and township health centers). A total of 51 primary care sites are randomized to three groups, with 17 sites assigned to group A (use a CDSS based on clinical guidelines and machine learning), 17 sites to group B (use a CDSS based on guidelines, hemodynamic parameters and ML), and the remaining 17 sites to the control group.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. 35 โ‰ค Age \< 80 years. 2. Regularly attend the clinic for hypertension treatment during the study period, without plans of traveling during the study period. 3. Diagnosed with hypertension, with SBP โ‰ฅ140mmHg at screening. 4. Currently taking 0 or 2 classes of antihypertensive medications (A/C/D), with or without concurrent use of class B. 5. Willing to participate in the trial and capable of providing written informed consent. Exclusion Criteria: 1. Physician-diagnosed or suspected secondary hypertension (e.g., hypertension caused by renal disease, renal artery stenosis, aortic stenosis, primary aldosteronism, pheochromocytoma/paraganglioma, Cushing's syndrome, thyroid dysfunction, intracranial disease, drug-induced, or rare monogenic genetic disease). 2. SBP โ‰ฅ180mmHg and/or DBP โ‰ฅ110mmHg at the screening visit. 3. Suspected or diagnosed white coat hypertension. 4. History of coronary heart disease. 5. History of heart failure. 6. Intolerance to 2 or more classes of A, C,D antihypertensive medications. 7. Currently taking antihypertensive medications other than class A,B,C and D. 8. Diagnosed chronic kidney disease, estimating Glomerular Filtration Rate (eGFR)\< 60 ml/minยท1.73m2, or receiving dialysis. 9. Serious medical conditions (e.g., malignant cancer and hepatic dysfunction) 10. Currently in an acute episode of disease (e.g, new-onset cardiovascular and cerebrovascular disease occurred within 3 months). 11. Cognitive or communicative disorders. 12. Currently pregnant or breastfeeding or planning a pregnant or breastfeeding during the study. 13. Reluctant to take antihypertensive medications or have poor compliance with previous treatment. 14. Participating in other clinical trials.
๐Ÿ’Š

What it tests

  • Group A (clinical guideline+machine learning)
  • Group B (clinical guideline+impedance cardiograph+machine learning)
  • Group C (usual care)
๐Ÿ“

Where

1 site
Fuwai Shenzhen Hospital, Chinese Academy of Medical Sciences
Shenzhen, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy